ReviewPain medicine (Malden, Mass.)2020
Understanding Buprenorphine for Use in Chronic Pain: Expert Opinion.
Review in Pain medicine (Malden, Mass.), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
61 citing papers in PubMed, 2 syntheses or guidelines pooled it, 123 citations in OpenAlex.
- Buprenorphine initiation strategies for opioid use disorder and pain management: A systematic review.Pharmacotherapy · 2022Pooled it
- Evaluation of Buprenorphine Rotation in Patients Receiving Long-term Opioids for Chronic Pain: A Systematic Review.JAMA network open · 2021Pooled it
- A qualitative study examining barriers to buprenorphine for pain management in patients with end stage kidney disease undergoing hemodialysis.The journal of pain · 2026Article
- Patient Profiles of Buprenorphine Initiators in General Healthcare Settings: A Latent Class Approach.Journal of general internal medicine · 2026Article
- Can Buprenorphine Be Overdosed? The Ceiling Effect and Its Clinical Implications.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Buprenorphine Products for the Treatment of Pain: Relative Risk of Abuse and Related Clinical Outcomes Compared to Full μ-Opioid Agonist Medications.Pain and therapy · 2026Article
- Feasibility and Preliminary Efficacy of Empowered Relief in Patients With Chronic Pain Taking Methadone or Buprenorphine: Single-Arm National Pilot Study.JMIR formative research · 2026Article
- Statewide trends in access to medications for opioid use disorder (moud) among adolescents with opioid use disorders in Indiana.Drug and alcohol dependence reports · 2026Article
- Iatrogenic physiologic opioid dependence masquerading as recurrent acute pancreatitis flares: case series.Addiction science & clinical practice · 2026Article
- Clinical perspectives: navigating buprenorphine formulations for pain treatment and opioid use disorder-a case-based approach.Pain medicine (Malden, Mass.) · 2026Article
- Investigating mitophagy mechanisms in bronchopulmonary dysplasia through bioinformatics.Pediatric research · 2026Article
- Machine Learning Model for Predicting Suicide Risks Among Patients With Posttraumatic Stress Disorder Who Received Opioids.Depression and anxiety · 2026Article
- Opioid receptor agonist-antagonists in pain management: receptor specific mechanisms, dose response relationships, and clinical combination strategies.Frontiers in pain research (Lausanne, Switzerland) · 2026Review
- Development and Validation of an Electronic Health Record-Based Algorithm for Identifying Patients With Long-Term Opioid Therapy: Cross-Sectional Study.Journal of medical Internet research · 2025Article
- Buvidal/Brixadi - a long-acting injectable buprenorphine formulation for the treatment of opioid dependence.Pain management · 2025Review
- Evaluating buprenorphine to treat cancer pain: a systematic review protocol.Systematic reviews · 2025Article
- The psychosocial pain management to improve opioid use disorder treatment outcomes study: Protocol for a randomized controlled trial.Contemporary clinical trials · 2025Article
- Buprenorphine Is Associated With Lower Home Opioid Use and Acute Care Utilization in Sickle Cell Disease.Pain management nursing : official journal of the American Society of Pain Management Nurses · 2025Article
- Subcutaneous Buprenorphine Is an Acceptable Preoperative Analgesic in Pregnant Ewes Undergoing Hysterotomy (Ovis aries).Journal of the American Association for Laboratory Animal Science : JAALAS · 2025Article
- Biased agonism in psychopharmacology: an opportunity to improve efficacy and safety of treatments.CNS spectrums · 2025Review
1 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 7 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveAn expert panel convened to reach a consensus on common misconceptions surrounding buprenorphine, a Schedule III partial µ-opioid receptor agonist indicated for chronic pain. The panel also provided clinical recommendations on the appropriate use of buprenorphine and conversion strategies for switching to buprenorphine from a full µ-opioid receptor agonist for chronic pain management.
methodsThe consensus panel met on March 25, 2019, to discuss relevant literature and provide recommendations on interpreting buprenorphine as a partial µ-opioid receptor agonist, prescribing buprenorphine before some Schedule II, III, or IV options, perioperative/trauma management of patients taking buprenorphine, and converting patients from a full µ-opioid receptor agonist to buprenorphine.
resultsThe panel recommended that buprenorphine's classification as a partial µ-opioid receptor agonist not be clinically translated to mean partial analgesic efficacy. The panel also recommended that buprenorphine be considered before some Schedule II, III, or IV opioids in patients with a favorable risk/benefit profile on the basis of metabolic factors, abuse potential, and tolerability and that buprenorphine be continued during the perioperative/trauma period. In addition, switching patients from a full µ-opioid receptor agonist to buprenorphine should be considered with no weaning period at starting doses that are based on the previous opioid dose.
conclusionsThese recommendations provide a framework for clinicians to address most clinical scenarios regarding buprenorphine use. The overall consensus of the panel was that buprenorphine is a unique Schedule III opioid with favorable pharmacologic properties and a safety profile that may be desirable for chronic pain management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.